Nacubactam

Synonym(s): OP0595  |  RG6080  |  FPI-1459

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Spectrum of activity:	Gram-negative
Details of activity:	DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and inhibits penicillin binding protein 2 in Enterobacteriaceae
Combined with other compounds:	Yes
Description:	Synthetic compound. In clinical development in fixed combination with meropenem
Institute where first reported:	Fedora Pharmaceuticals, Meiji Seika Pharma, Roche
Year first mentioned:	2015
Highest developmental phase:	Phase 3 (NCT05905055)
Development status:	Active (as of 2022)

Chemical structure(s):
Canonical SMILES:	C1C[C@@H](C(=O)NOCCN)N2C[C@@H]1N(C2=O)OS(=O)(=O)O
Isomeric SMILES:	C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NOCCN
InChI:	InChI=1S/C9H16N4O7S/c10-3-4-19-11-8(14)7-2-1-6-5-12(7)9(15)13(6)20-21(16,17)18/h6-7H,1-5,10H2,(H,11,14)(H,16,17,18)/t6-,7+/m1/s1
InChI Key:	RSBPYSTVZQAADE-RQJHMYQMSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/Nacubactam

External links:
Guide to Pharmacology:	nacubactam
Main Source:	https://pubmed.ncbi.nlm.nih.gov/30590470/
Citations:	https://journals.asm.org/doi/10.1128/AAC.02229-19 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532682/